|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Binefa G, Rodríguez-Moranta F, Teule A and
Medina-Hayas M: Colorectal cancer: From prevention to personalized
medicine. World J Gastroenterol. 20:6786–6808. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang
S, Xiong Y and Wang D: Predictive value of APE1, BRCA1, ERCC1 and
TUBB3 expression in patients with advanced non-small cell lung
cancer (NSCLC) receiving first-line platinum-paclitaxel
chemotherapy. Cancer Chemother Pharmacol. 74:777–786. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ruzzo A, Graziano F, Loupakis F, Rulli E,
Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P,
Bisonni R, et al: Pharmacogenetic profiling in patients with
advanced colorectal cancer treated with first-line FOLFOX-4
chemotherapy. J Clin Oncol. 25:1247–1254. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Azuma K, Sasada T, Kawahara A, Takamori S,
Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, et al:
Expression of ERCC1 and class III beta-tubulin in non-small cell
lung cancer patients treated with carboplatin and paclitaxel. Lung
Cancer. 64:326–333. 2009. View Article : Google Scholar
|
|
6
|
Shirota Y, Stoehlmacher J, Brabender J,
Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg
PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict
survival for colorectal cancer patients receiving combination
oxaliplatin and fluorouracil chemotherapy. J Clin Oncol.
19:4298–4304. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li P, Fang YJ, Li F, Ou QJ, Chen G and Ma
G: ERCC1, defective mismatch repair status as predictive biomarkers
of survival for stage III colon cancer patients receiving
oxaliplatin-based adjuvant chemotherapy. Br J Cancer.
108:1238–1244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Akita H, Zheng Z, Takeda Y, Kim C, Kittaka
N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, et al:
Significance of RRM1 and ERCC1 expression in resectable pancreatic
adenocarcinoma. Oncogene. 28:2903–2909. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parker AL, Kavallaris M and McCarroll JA:
Microtubules and their role in cellular stress in cancer. Front
Oncol. 4:1532014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo J, Qiang M and Ludueña RF: The
distribution of β-tubulin isotypes in cultured neurons from
embryonic, newborn, and adult mouse brains. Brain Res. 1420:8–18.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Verdier-Pinard P, Pasquier E, Xiao H, Burd
B, Villard C, Lafitte D, Miller LM, Angeletti RH, Horwitz SB and
Braguer D: Tubulin proteomics: Towards breaking the code. Anal
Biochem. 384:197–206. 2009. View Article : Google Scholar
|
|
12
|
Portyanko A, Kovalev P, Gorgun J and
Cherstvoy E: beta(III)-tubulin at the invasive margin of colorectal
cancer: Possible link to invasion. Virchows Arch. 454:541–548.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Giarnieri E, De Francesco GP, Carico E,
Midiri G, Amanti C, Giacomelli L, Tucci G, Gidaro S, Stroppa I,
Gidaro G, et al: Alpha- and beta-tubulin expression in rectal
cancer development. Anticancer Res. 25:3237–3241. 2005.PubMed/NCBI
|
|
14
|
Carles G, Braguer D, Dumontet C, Bourgarel
V, Gonçalves A, Sarrazin M, Rognoni JB and Briand C:
Differentiation of human colon cancer cells changes the expression
of beta-tubulin isotypes and MAPs. Br J Cancer. 80:1162–1168. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Colucci G, Gebbia V, Paoletti G, Giuliani
F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione
L, et al: Gruppo Oncologico Dell'Italia Meridionale: Phase III
randomized trial of FOLFIRI versus FOLFOX4 in the treatment of
advanced colorectal cancer: A multicenter study of the Gruppo
Oncologico Dell'Italia Meridionale. J Clin Oncol. 23:4866–4875.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tóth C, Meinrath J, Herpel E, Derix J,
Fries J, Buettner R, Schirmacher P and Heikaus S: Expression of the
apoptosis repressor with caspase recruitment domain (ARC) in liver
metastasis of colorectal cancer and its correlation with DNA
mismatch repair proteins and p53. J Cancer Res Clin Oncol.
142:927–935. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grimminger PP, Shi M, Barrett C, Lebwohl
D, Danenberg KD, Brabender J, Vigen CL, Danenberg PV, Winder T and
Lenz HJ: TS and ERCC-1 mRNA expressions and clinical outcome in
patients with metastatic colon cancer in CONFIRM-1 and -2 clinical
trials. Pharmacogenomics J. 12:404–411. 2012. View Article : Google Scholar
|
|
18
|
Choueiri MB, Shen JP, Gross AM, Huang JK,
Ideker T and Fanta P: ERCC1 and TS Expression as Prognostic and
Predictive Biomarkers in Metastatic Colon Cancer. PLoS One.
10:e01268982015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Umar A, Boland CR, Terdiman JP, Syngal S,
de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ,
Hamelin R, et al: Revised Bethesda Guidelines for hereditary
nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite
instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ting S1, Mairinger FD, Hager T, Welter S,
Eberhardt WE, Wohlschlaeger J, Schmid KW and Christoph DC: ERCC1,
MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins
associated with response and outcome to platinum-based chemotherapy
in malignant pleural mesothelioma. Clin Lung Cancer. 14:558–567.e3.
2013. View Article : Google Scholar
|
|
21
|
Yu Y, Wang Y, Ren X, Tsuyada A, Li A, Liu
LJ and Wang SE: Context-dependent bidirectional regulation of the
MutS homolog 2 by transforming growth factor β contributes to
chemoresistance in breast cancer cells. Mol Cancer Res.
8:1633–1642. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide
T, Mitsuno M and Miyazaki K: Ribonucleotide reductase subunit M1 is
a possible chemoresistance marker to gemcitabine in biliary tract
carcinoma. Oncol Rep. 20:279–286. 2008.PubMed/NCBI
|
|
23
|
Porter LA and Lee JM: Alpha-, beta-, and
gamma-tubulin polymerization in response to DNA damage. Exp Cell
Res. 270:151–158. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hassen S, Ali N and Chowdhury P: Molecular
signaling mechanisms of apoptosis in hereditary non-polyposis
colorectal cancer. World J Gastrointest Pathophysiol. 3:71–79.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: The role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Knipling L and Wolff J: Direct interaction
of Bcl-2 proteins with tubulin. Biochem Biophys Res Commun.
341:433–439. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McCarroll JA, Sharbeen G, Liu J, Youkhana
J, Goldstein D, McCarthy N, Limbri LF, Dischl D, Ceyhan GO, Erkan
M, et al: βIII-tubulin: A novel mediator of chemoresistance and
metastases in pancreatic cancer. Oncotarget. 6:2235–2249. 2015.
View Article : Google Scholar
|
|
28
|
Raspaglio G, Filippetti F, Prislei S,
Penci R, De Maria I, Cicchillitti L, Mozzetti S, Scambia G and
Ferlini C: Hypoxia induces class III beta-tubulin gene expression
by HIF-1alpha binding to its 3′ flanking region. Gene. 409:100–108.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Raspaglio G, De Maria I, Filippetti F,
Martinelli E, Zannoni GF, Prislei S, Ferrandina G, Shahabi S,
Scambia G and Ferlini C: HUR regulates beta-tubulin isotype
expression in ovarian cancer. Cancer Res. 70:5891–5900. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Van Cutsem E, Cervantes A and Nordlinger
B: Metastatic colorectal cancer: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 25(Suppl 3):
iii1–iii9. 2014. View Article : Google Scholar : PubMed/NCBI
|
